HER2-positive Gastroesophageal Junction Adenocarcinoma
2 clinical trials · Condition
◉ Watch HER2-positive Gastroesophageal Junction Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens (NCT06572319) | Zhejiang Cancer Hospital | 2024-09-01 |
| A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) (NCT05993234) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-12-05 |
Track HER2-positive Gastroesophageal Junction Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.